logo
Saptalis Pharmaceuticals Launches Fluoxetine Oral Solution, USP 20 mg/5 mL

Saptalis Pharmaceuticals Launches Fluoxetine Oral Solution, USP 20 mg/5 mL

Yahoo18-06-2025
HAUPPAUGE, N.Y., June 18, 2025--(BUSINESS WIRE)--Saptalis Pharmaceuticals, LLC. is pleased to announce the commercial launch of Fluoxetine Oral Solution, USP 20 mg/5 mL, a prescription-only selective serotonin reuptake inhibitor (SSRI) developed to treat a range of mental health conditions effectively. This oral formulation is designed to support flexible and individualized treatment, particularly for patients who experience difficulty swallowing solid dosage forms.
Fluoxetine Oral Solution is indicated for the following conditions:
Acute and maintenance treatment of Major Depressive Disorder (MDD)
Acute and maintenance treatment of Obsessive-Compulsive Disorder (OCD)
Acute and maintenance treatment of Bulimia Nervosa
Acute treatment of Panic Disorder, with or without agoraphobia
"We are excited to expand our product portfolio with the introduction of Fluoxetine Oral Solution," said Polireddy Dondeti, Ph.D., President and CEO, of Saptalis Pharmaceuticals, LLC. "This launch reflects our ongoing commitment to providing high-quality, accessible medications that meet the evolving needs of both patients and healthcare professionals."
Fluoxetine Oral Solution, USP 20 mg/5 mL is available by prescription and should only be used under the guidance of a licensed healthcare provider to ensure safe and effective treatment.
For full prescribing information or to learn more, please visit www.saptalis.com or contact us at info@saptalis.com.
About Saptalis Pharmaceuticals, LLC.
Saptalis Pharmaceuticals, LLC. is a rapidly growing company focused on the development, manufacturing, and commercialization of specialty pharmaceutical products, including complex and high-quality generics, with particular expertise in liquid and semi-solid dosage forms. Headquartered in Hauppauge, New York, Saptalis operates fully equipped R&D laboratories and a state-of-the-art commercial manufacturing facility compliant with U.S. FDA cGMP standards. The company is dedicated to delivering innovative solutions that enhance patient care and improve treatment outcomes.
www.Saptalis.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20250618093628/en/
Contacts
Peruvemba SatishChief Financial Officer & Chief Commercial Officer(631) 231 2751 x211info@saptalis.com
Error al recuperar los datos
Inicia sesión para acceder a tu cartera de valores
Error al recuperar los datos
Error al recuperar los datos
Error al recuperar los datos
Error al recuperar los datos
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Sell HIMS Stock Ahead of Its Earnings?
Sell HIMS Stock Ahead of Its Earnings?

Forbes

time28 minutes ago

  • Forbes

Sell HIMS Stock Ahead of Its Earnings?

Hims & Hers Health (NYSE:HIMS) is set to announce its earnings on Monday, August 4, 2025. Historically, HIMS stock has reacted unfavorably to earnings announcements. Since 2021, the stock has recorded a negative one-day return in 53% of instances after results. The median one-day decline has amounted to -5.8%, with a maximum one-day decrease of -22.3%. For traders focused on events, grasping these historical trends can be beneficial. While the actual results compared to consensus and expectations will be vital, there are two main strategies to contemplate: Analysts expect HIMS to report earnings of $0.23 per share on revenues of $552 million. This would mark substantial growth compared to the same quarter last year, which recorded earnings of $0.16 per share on revenues of $315 million. A possible positive factor for Hims & Hers' sales growth momentum is the reported underperformance of Novo Nordisk's weight loss medication in the U.S. due to the presence of compounded versions. Regarding fundamentals, HIMS has a market capitalization of $15 billion. Over the past twelve months, the company generated $1.8 billion in revenue and was operationally profitable, reporting $110 million in operating profits and a net income of $164 million. However, if you're looking for upside with less volatility than individual stocks, the Trefis High Quality portfolio offers an alternative — it has outperformed the S&P 500 and achieved returns exceeding 91% since its inception. Additionally, see – Is There More Upside For MSFT Stock? Review earnings reaction history of all stocks HIMS Stock Historical Likelihood of Positive Post-Earnings Return Here are some insights on one-day (1D) post-earnings returns: Additional information regarding the observed 5-Day (5D) and 21-Day (21D) returns post earnings is summarized along with the statistics in the table below. HIMS Stock Correlation Between 1D, 5D, and 21D Historical Returns A comparatively lower-risk strategy (though not effective if the correlation is weak) is to understand the relationship between short-term and medium-term returns post earnings, identify a pair that has the highest correlation, and perform the corresponding trade. For instance, if 1D and 5D exhibit the highest correlation, a trader can take a "long" position for the next 5 days if the 1D post-earnings return is positive. Here is some correlation information based on a 5-year and 3-year (more recent) timeframe. Note that the correlation 1D_5D denotes the relationship between 1D post-earnings returns and subsequent 5D returns. Discover more about the Trefis RV strategy that has outperformed its all-cap stocks benchmark (a blend of the S&P 500, S&P mid-cap, and Russell 2000), delivering strong results for investors. Additionally, if you seek upside with a smoother experience than an individual stock like Hims & Hers Health, consider the High Quality portfolio, which has surpassed the S&P and yielded >91% returns since its inception.

Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on August 13, 2025
Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on August 13, 2025

Yahoo

timean hour ago

  • Yahoo

Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on August 13, 2025

Conference Call and Webcast at 8:30 AM Eastern Time NEW YORK, July 30, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced that it will host a business update conference call and webcast on Wednesday, August 13, 2025, at 8:30 AM ET. During the call, Lishan Aklog, M.D., Lucid's Chairman and Chief Executive Officer, will provide a business update, including an overview of the Company's operations and continued growth strategy. In addition, Dennis McGrath, Lucid's Chief Financial Officer, will discuss the Company's second quarter 2025 financial results. The webcast will be available at the investor relations section of the Company's website at Alternatively, to access the conference call by telephone, U.S.-based callers should dial 1-800-836-8184 and international listeners should dial 1-646-357-8785. All listeners should provide the operator with the conference call name "Lucid Diagnostics Business Update" to join. Following the conclusion of the conference call, a replay will be available for 30 days on the investor relations section of the Company's website at About Lucid DiagnosticsLucid Diagnostics Inc. is a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM). Lucid is focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, who are at risk of developing esophageal precancer and cancer. Lucid's EsoGuard® Esophageal DNA Test, performed on samples collected in a brief, noninvasive office procedure with its EsoCheck® Esophageal Cell Collection Device, represent the first and only commercially available tools designed with the goal of preventing cancer and cancer deaths through widespread, early detection of esophageal precancer in at-risk patients. For more information, please visit and for more information about its parent company PAVmed, please visit View original content to download multimedia: SOURCE Lucid Diagnostics Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Stuck with stiff joints? This 5-move kettlebell trainer workout is your range-of-motion reset
Stuck with stiff joints? This 5-move kettlebell trainer workout is your range-of-motion reset

Yahoo

timean hour ago

  • Yahoo

Stuck with stiff joints? This 5-move kettlebell trainer workout is your range-of-motion reset

When you buy through links on our articles, Future and its syndication partners may earn a commission. If your hips feel tighter than your work schedule, you're not alone. Hours spent sitting at a desk, commuting, or even just lounging on the sofa can leave your hips stiff, your lower back grumbling, and your movement feeling anything but nimble. To help loosen things up and strengthen the muscles around your hips, personal trainer Shaina Fata has created a five-move mobility routine using a kettlebell. If you're in the market for equipment, we've tested the best kettlebells for home workouts. Fata's routine is designed to improve lower body joint health and build functional strength using just one weight and a jump box. If you don't have a box, try a sturdy step, low bench, or even a wide staircase. There are no quick fixes when it comes to improving mobility and strength. Things like building range of motion take time and consistency. But this routine is a great place to start, especially if you're feeling stiff and want to move with more freedom. Watch trainer Shaina Fata's mobility and strength routine for the hips What are the benefits This five-move routine may look simple on paper, but each exercise is carefully chosen to target common trouble spots like tight hips, stiff joints, and underused glutes. It includes moves like kettlebell windmills and halos which will challenge your balance and coordination while opening up the shoulders and hips. You'll also tune into some deep squats and kneeling hip shifts that will encourage mobility in the lower body. Meanwhile the high box step-ups add a dose of functional strength which the benefits will carry over into everyday movement. These exercises are most effective when done with proper form, and slowing down each move can help you focus on control rather than rushing through the reps. If you are new to mobility work or kettlebell training, it's worth taking a moment to watch trainer Fata's demonstrations closely. These exercises are most effective when done with proper form, and slowing down each move can help you focus on control rather than rushing through the reps. Pay attention to how Fata moves with intention throughout the routine. This kind of focus is key to building strength and improving range of motion over time. The kettlebell is not just there to add weight. Adding load challenges your stability, activates deeper muscle engagement, and helps you build strength through a greater range of motion. It can also improve posture, increase core strength, and encourage better joint control. Quick note: this routine may not be suitable for everyone. Deep squats and weighted mobility work can feel too intense for beginners or anyone dealing with pain or injury. If that sounds familiar, try one of our picks of bodyweight mobility routines or explore lower-impact strength workouts to build a foundation first. More from Tom's Guide This mobility test takes just seconds — and it could predict how well you'll age Hate sit-ups? Study shows this is the only activity you need to strengthen your core Want to protect your brain as you age? Science says to start with this routine

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store